Target ALS raises $250 million to accelerate ALS research
Target ALS has reached its capital campaign goal of $250 million to accelerate research and fuel scientific breakthroughs in…
Articles by Steve Bryson, PhD
Epigenetics may be key to ALS disease progression, study shows
Epigenetic changes — chemical modifications in DNA that alter gene activity — in nerve cells from people with amyotrophic…
Qalsody slows ALS disease progression in real-world settings
Treatment with Qalsody (tofersen) in the real world slowed disease progression in people with amyotrophic lateral sclerosis (ALS)…
Health Canada agrees to reconsider request for masitinib approval
The developer of the add-on treatment masitinib for amyotrophic lateral sclerosis (ALS) has been given the go-ahead to…
Relyvrio withdrawn from US, Canada after Phase 3 trial results
Relyvrio (sodium phenylbutyrate and taurursodiol), an approved treatment for amyotrophic lateral sclerosis (ALS), was voluntarily removed from the…
Signs of frontotemporal dementia seen in about 35% of ALS patients
More than a third of people diagnosed with amyotrophic lateral sclerosis (ALS) also showed signs of…
AcuraStem awarded NIH, DOD grants to boost ALS therapies
AcuraStem has secured nearly $7 million in grant funding from the National Institutes of Health (NIH)…
Cigarette smoking tied to greater risk of ALS, especially for women
Cigarette smoking, either currently or in the past, significantly increases the likelihood of developing amyotrophic lateral sclerosis (ALS), particularly…
ALS Canada awards $200K to speed global disease research
The ALS Society of Canada (ALS Canada) has awarded two expedited grants totaling $200,000 to international researchers seeking to…
CHMP delays opinion on masitinib, up for conditional EU approval
A European Medicines Agency (EMA) committee again has delayed issuing an opinion on whether to grant conditional approval to…